Skip to main content
. 2016 Sep 15;20(12):2374–2383. doi: 10.1111/jcmm.12931

Figure 2.

Figure 2

Inhibition of PCSK9 expression returned LDLR expression and LDL uptake during CRP treatment in HepG2 cells. (A) (B) Western blot analyses of the protein expressions of PCSK9 and LDLR in HepG2 cells transfected with siRNA‐PCSK9 (40 nM) and then treated with CRP (10 μg/ml) for 24 hrs. (C) Representative fluorescence microscopy images of cell‐associated Dil‐LDL (red), Hoechst‐stained nuclei (blue) and the overlay. (D) Fluorescence of isopropanol‐extracted Dil (520–570 nm, normalized to the cell protein). Values were the representative results of three independent experiments (mean ± SEM). Significance: **P < 0.01 versus control; # P < 0.05, ## P < 0.01 versus the CRP‐treated group. CRP, C‐reactive protein; siPCSK9, small interfering pro‐protein convertase subtilisin/kexin type 9; LDLR, low‐density lipoprotein receptor.